Vitamin B12 repurposed to hunt glioblastoma, the most feared brain cancer

Introduction: a pharmacy vitamin against the worst brain cancer

A familiar compound, an unprecedented target

Glioblastoma remains, even today, one of the most aggressive and hardest-to-treat forms of brain cancer in oncology. It is in this context that a study published on April 2, 2026 in the scientific journal Oncoscience drew attention: it explores a modified version of vitamin B12, called nitrosylcobalamin (NO-Cbl), capable of crossing the blood-brain barrier and specifically targeting tumor tissue.

The study was led by Joseph A. Bauer, principal researcher at Nitric Oxide Services, LLC and affiliated with the Cleveland Clinic Foundation Taussig Cancer Center. The full title of the publication, "Selective blood-brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma," sums up the ambition of the project: turning a mundane vitamin into a therapeutic Trojan horse against one of the deadliest tumors in the human body.

Why this approach changes the way we think about treatment

The main obstacle to treating glioblastoma is not just the aggressiveness of the tumor itself: it is the extreme difficulty most drugs face crossing the blood-brain barrier, the protective membrane that isolates the brain from general blood circulation. Many treatments effective in the lab simply fail because they never reach the tumor in sufficient concentration.

It is precisely this bottleneck that nitrosylcobalamin appears able to bypass, by exploiting a fundamental biological need of fast-growing cancer cells: their outsized appetite for cobalamin, a metabolic need that researchers have learned to turn against the tumor itself. I always find this type of scientific approach fascinating: take a weakness of cancer, its hunger for certain nutrients, and turn it into a way in to attack it, rather than looking for an entirely new poison.

How nitrosylcobalamin works

A metabolic Trojan-horse principle

Cancer cells, because of their rapid division, have a heightened need for cobalamin and for so-called "one-carbon" metabolism, essential to DNA synthesis. Nitrosylcobalamin exploits this vulnerability by masquerading as ordinary vitamin B12, allowing it to be preferentially absorbed by tumor cells through the same biological transporters, notably transcobalamin II and its receptor CD320, which are overexpressed in many cancers.

Once inside the cancer cell, the molecule releases nitric oxide, a compound capable of triggering programmed cell death through several distinct biological mechanisms, notably activation of caspase-8 and inhibition of the NF-κB survival pathway.

Selective accumulation confirmed in the lab

According to data published by Bauer's team, experiments conducted on glioblastoma-bearing rats showed that nitrosylcobalamin does indeed cross the blood-brain barrier after systemic administration, and accumulates preferentially in tumor tissue rather than in surrounding healthy tissue. Nitrate levels remained elevated in the tumor even 24 hours after treatment, while they dropped much faster in normal tissue.

This selective retention is an encouraging signal for researchers, since it suggests the treatment could concentrate its toxic effect on the tumor while sparing more of the surrounding healthy brain tissue. This is exactly the kind of selectivity the neuro-oncology community has been waiting for, for decades: a treatment that hits the tumor hard without destroying a brain already weakened by the disease along the way.

Encouraging results in synergy with existing treatments

Amplified power with TRAIL and temozolomide

One of the most interesting findings of the study concerns the combination of nitrosylcobalamin with two treatments already used or studied against glioblastoma: the protein TRAIL and standard chemotherapy drug temozolomide. In human glioblastoma cell cultures, notably the U87 and D54 lines, adding NO-Cbl produced markedly greater suppression of tumor proliferation than either treatment achieved alone.

A so-called combination index analysis confirmed synergistic interactions across several dosage ranges, a statistically solid result that strengthens the scientific credibility of this combined approach.

Tackling resistance, glioblastoma's real challenge

Temozolomide, while it remains a pillar of standard glioblastoma treatment, frequently runs into therapeutic resistance that limits its long-term effectiveness. Researchers suggest nitrosylcobalamin could help overcome some of these resistance mechanisms, notably through S-nitrosylation, a chemical process that would strengthen TRAIL receptor signaling even in tumor cells that have become resistant to temozolomide.

If this approach is confirmed in later studies, it could offer an additional option for patients whose tumor has stopped responding to first-line treatments. This may be the most promising aspect of this research: not just a new poison against the tumor, but a way to reawaken the effectiveness of existing treatments that had stopped working.

A second, parallel path: high-dose niacin

The University of Calgary's clinical trial

Notably, nitrosylcobalamin is not the only vitamin-based approach currently being explored against glioblastoma. A team from the University of Calgary, led notably by researcher Roldan Urgoiti, is running a parallel clinical trial exploring high-dose niacin as an adjunct treatment. Among the first 24 patients treated as part of this trial, 82% showed no disease progression at six months, compared with roughly 54% in historical comparison cohorts.

These two distinct approaches, one based on modified vitamin B12, the other on high-dose vitamin B3, illustrate a renewed scientific interest in simple, well-known molecules repurposed in novel ways against one of the hardest cancers to treat.

Necessary caution around high doses

The niacin trial also revealed side effects worth watching: skin flushing typical of niacin, and in two cases, serious blood-related effects at high doses, which led the team to set a maximum tolerated dose of 2,000 milligrams per day. Researcher Urgoiti explicitly warned against self-medication: very high doses of vitamins, including niacin, can be dangerous and should only be used under strict medical supervision.

This reminder is essential in a context where the temptation toward self-medication with vitamin supplements could spread following media coverage of this research. This is a point I want to stress as firmly as possible: nobody should rush to buy megadoses of vitamins at the pharmacy after reading this article. What works in a supervised clinical trial can become dangerous through unsupervised self-medication.

Glioblastoma, a formidable opponent worth understanding

A prognosis that remains grim despite advances

Glioblastoma remains one of the most aggressive primary brain tumors in adults, with a prognosis that remains grim despite decades of research. The current standard treatment generally combines surgery, radiotherapy, and chemotherapy with temozolomide, but relapses remain common and median survival remains limited for the majority of diagnosed patients.

It is this difficult clinical reality that explains the considerable interest generated by any new therapeutic lead, however preliminary, within the community of patients, families, and clinicians specializing in neuro-oncology. I fully understand why every new glioblastoma study makes so much noise: it's a disease that leaves too little room for error and too little time for the families facing it.

Why the blood-brain barrier complicates everything

The blood-brain barrier evolved to protect the brain from toxins and pathogens circulating in the blood, but this same protection also prevents most therapeutic molecules from reaching brain tumors in sufficient concentration. This is one of the main reasons so many treatments promising in the lab fail once tested in complete living organisms.

Any molecule able to selectively cross this barrier while sparing healthy tissue therefore represents, on its own, a significant technical advance, regardless of its actual anticancer effectiveness.

What this study cannot yet claim

A pilot study, not a validated treatment

It is essential to repeat this clearly: the authors themselves explicitly describe their work as a translational pilot study, not a definitive clinical demonstration. The results obtained concern cells cultured in the lab and tumor-bearing rats, not yet human patients with glioblastoma.

The authors themselves state that further research remains necessary before any clinical application, including orthotopic validation, dose optimization, and extended monitoring of nitric oxide activity in animal models closer to human clinical reality.

The realistic timeline before possible human use

According to statements from Bauer himself, the Cleveland Clinic Foundation team plans to launch phase II clinical trials by the end of 2026 to confirm, this time in humans, the treatment's efficacy and safety. Bauer summed up the situation with commendable scientific honesty: the preclinical data are very promising, but they must now be validated in patients.

This lag, between the publication of a promising preclinical study and a treatment available to patients, illustrates a reality the general public often underestimates: the path from the lab to the patient's bedside is generally measured in years, sometimes decades. I always prefer to temper the legitimate enthusiasm these discoveries generate: between a promising result in rats and an approved treatment in humans lies an enormous gap that too many sensationalist articles choose to ignore.

The team behind the discovery

A collaboration among several leading institutions

The study benefited from collaboration among several researchers recognized in their respective fields. The lab of Michael A. Vogelbaum, now affiliated with the Moffitt Cancer Center, ran the animal experiments essential to validating the crossing of the blood-brain barrier. Daniel J. Linder, of the Cleveland Clinic, contributed to evaluating nitrosylcobalamin as an anticancer agent.

The company Genentech, through researcher Avi Ashkenazi, also supplied the TRAIL protein needed for the combination-therapy experiments, illustrating the collaborative nature of this kind of translational research that often crosses boundaries between academic institutions and the pharmaceutical industry.

Why this kind of collaboration matters

This pooling of resources, animal expertise, medicinal chemistry skills, and specialized reagents shows how modern cancer research rarely depends on a single isolated lab. It is often the convergence of several complementary areas of expertise that pushes a hypothesis from the theoretical stage toward robust experimental validation.

This collaborative dynamic is especially important for rare and complex cancers like glioblastoma, where the limited number of patients makes every piece of experimental data valuable. I find it reassuring to see such diverse institutions, clinical, academic, and industrial, collaborating on such a difficult problem rather than engaging in sterile competition.

The broader context of brain cancer research

A field long marked by repeated failures

Research into glioblastoma has long been marked by a series of disappointing clinical trials, with many molecules promising in the lab failing to demonstrate significant clinical benefit once tested on actual patients. This accumulation of negative results has made the scientific community naturally cautious toward any new announcement, however exciting it may appear on the surface.

It is in this climate of methodological caution that the nitrosylcobalamin announcement should be received: as a serious, scientifically documented lead, but not as an already-achieved breakthrough.

The role of research funding bodies

Organizations like Diabetes UK for other diseases, or foundations specializing in brain cancer, play a decisive role in funding this kind of basic research, often considered too risky by the traditional pharmaceutical industry at such an early stage. Continued support for this preliminary work directly determines science's ability to explore original leads like this one.

Without this funding for exploratory research, potentially transformative discoveries would likely stay in lab drawers, lacking the means to be developed further. This basic research funding, often invisible to the general public, nonetheless deserves attention: it is what makes possible every discovery that, years later, ends up saving lives.

What patients and families should take away

Measured hope, not promises

For families facing a glioblastoma diagnosis, the temptation to cling to every new scientific announcement is perfectly understandable when confronting such a devastating disease. But journalistic responsibility requires presenting these advances with all the nuance they deserve: nitrosylcobalamin is not, as of today, an available treatment, nor has it even been tested in humans.

Patients currently undergoing treatment should continue following the protocols validated by their medical teams, without interrupting or altering their treatment based on a preclinical study, however promising it may look on paper.

The importance of following upcoming clinical trials

Families and patients interested in these approaches should instead turn to official clinical trial registries to check, when the time comes, whether phase II trials for nitrosylcobalamin or the University of Calgary niacin trial are accepting new participants who meet the inclusion criteria.

It is through this medically supervised channel that these experimental treatments could one day, should the results hold up, become safely accessible. I understand the distress of wanting to try everything in the face of such a devastating diagnosis. But it is precisely in these moments of vulnerability that one must be most wary of shortcuts, and favor supervised clinical trials over self-medication.

Methodological limits worth keeping in mind

Animal models that don't predict everything

Animal models, however useful for guiding research, never perfectly reproduce the biological complexity of human glioblastoma. Many molecules that showed spectacular efficacy in rats or mice later failed to demonstrate comparable benefit in humans, due to significant metabolic, immunological, and anatomical differences between species.

This methodological limitation does not invalidate the results obtained by Bauer's team, but it does require a cautious reading of their actual significance given the current state of knowledge.

The need for independent replication

As with any preliminary scientific discovery, validation by independent research teams, in other labs and with other experimental models, is an indispensable step before the scientific community grants broader credit to these initial results.

This requirement for replication, however frustrating for families awaiting quick solutions, remains the very foundation of rigorous scientific method, particularly crucial in a field as sensitive as neuro-oncology. The slowness of science frustrates everyone, myself included. But it is this very slowness that has, in the past, kept us from adopting treatments that seemed promising and turned out to be useless or even dangerous.

Other cancers targeted by the same strategy

A mechanism that goes beyond glioblastoma alone

The study by Bauer and his team did not limit its tests to glioblastoma. Using the NCI-60 cell-line panel, a standard benchmark in cancer research covering sixty types of human tumors, the researchers observed that nitrosylcobalamin displayed broad antitumor activity across multiple cancer types, not just central nervous system tumors.

Cell lines derived from the central nervous system, however, showed sensitivity judged intermediate compared to other cancer types tested in the same panel, a detail that tempers the enthusiasm without erasing it.

A potentially broader therapeutic platform

If this broad anticancer activity is confirmed in later studies, nitrosylcobalamin could eventually represent a therapeutic platform applicable to several cancers beyond glioblastoma alone, rather than a single-use molecule. The authors nonetheless remain cautious and, for now, are concentrating their efforts on brain-specific validation, given the particular clinical urgency this disease represents. If this lead delivers on its promise beyond glioblastoma, we could see the emergence of an entirely new class of treatments built on repurposed vitamins. That's the kind of scenario worth watching very closely in the years ahead.

The difference between deficiency and overdose in vitamin B12

A delicate balance to understand

It is important to clarify a common point of confusion among the general public: nitrosylcobalamin is not simply high-dose vitamin B12 that one could pick up at a pharmacy. It is a chemically modified molecule, designed in the lab to exploit specific metabolic pathways, radically different from a classic over-the-counter vitamin B12 supplement.

Taking ordinary vitamin B12 supplements will have no anticancer effect comparable to that observed with nitrosylcobalamin in this study, an essential nuance to avoid dangerous confusion among patients seeking quick fixes.

Why this distinction protects patients

This clarification is not a minor technicality: it directly protects patients from the temptation to self-administer massive doses of vitamin B12 based on a mistaken understanding of this research, a practice that would provide no documented anticancer benefit and could, in some cases, interfere with other ongoing treatments.

Oncology specialists systematically recommend never changing any supplementation regimen without first discussing it with the treating medical team.

Future cost and access, a question already on the table

Anticipating accessibility issues

Even if phase II clinical trials one day confirm the efficacy and safety of nitrosylcobalamin in humans, a separate question will arise immediately: that of the cost and accessibility of this treatment for all the patients who would need it, regardless of their financial means or national health system.

Recent oncology history is full of examples of innovative treatments whose efficacy has been proven, but whose price remains out of reach for a large share of patients, particularly in low- and middle-income countries.

Vigilance needed starting now

It would be premature to precisely anticipate the future price of a treatment still at the preclinical stage, but recent experience with other targeted cancer therapies justifies vigilance starting now on the part of regulators and health systems, to prevent access to this kind of innovation from reproducing inequalities already seen elsewhere in oncology. I would rather raise this question now than discover it too late: a remarkable scientific discovery changes nothing for a patient who cannot afford access to it.

What the scientific community expects next

Key next steps to watch

The neuro-oncology community is now watching for several specific milestones: the actual launch of the phase II trials announced by the Cleveland Clinic team, the publication of safety data from the first human patients treated, and possible independent replication of the preclinical results by other specialized labs in the field.

Each of these steps will represent an important test of whether this therapeutic lead can cross the gap that so often separates a promising lab discovery from a treatment actually available to patients.

Why patience remains the only reasonable option

For families and patients following this kind of scientific news with entirely understandable hope, the only reasonable attitude remains active patience: continuing to follow the validated treatments recommended by their medical teams, while staying informed about real advances, verified and published in serious scientific journals rather than relayed through unverified sources.

It is this balance between measured hope and scientific rigor that should guide media coverage of this kind of research, today and in the months ahead.

Conclusion: a scientific glimmer, not yet a treatment

What this research truly represents

Nitrosylcobalamin embodies a particularly elegant example of translational research: turning a fine-grained understanding of cancer cell metabolism into a targeted therapeutic strategy, while relying on a molecule derived from a vitamin already well known and extensively studied for decades. It is this kind of scientific creativity, grounded in precise biological mechanisms rather than hope alone, that has historically fueled genuine advances in oncology.

Combined with the parallel results obtained with high-dose niacin at the University of Calgary, this research suggests there remain unexplored avenues, even in molecules as common as B-group vitamins, for attacking one of the most feared cancers in modern medicine.

Patience and scientific vigilance

It will take several more years, and probably several successive clinical trials, before we know whether nitrosylcobalamin will deliver on its initial promise in human patients with glioblastoma. Until then, scientific caution must take precedence over media enthusiasm, without extinguishing the legitimate hope generated by any documented advance against this devastating disease. I'll close on a note of cautious hope: science advances in small, documented steps, rarely through sudden miracles. This study on vitamin B12 is a perfect example of that, and that is already a great deal.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my acknowledged biases

I am a generalist columnist, not a physician or oncology researcher. My role is to popularize scientific publications accessible to the public, relying on the original papers and institutional press releases, without having personally conducted expert-level critical analysis of the study's raw data.

My acknowledged bias is a sincere interest in medical advances that carry hope, tempered by a demand for caution against the risk of overpromising results from still-fragile preclinical findings.

What I don't know, and my method

I do not know whether nitrosylcobalamin will demonstrate efficacy in humans comparable to that observed in animals, nor what the actual timeline will be for the phase II clinical trials announced by the Cleveland Clinic team. No human data currently exist for this specific molecule in the treatment of glioblastoma.

My method consists of relying on the original scientific publication and on reliable journalistic coverage, explicitly flagging the preclinical stage of the research, and avoiding any language that would suggest imminent clinical availability that does not yet exist.

Sources

Primary sources

Oncoscience — Vitamin B12-based therapy shows tumor-targeting potential against glioblastoma, May 21, 2026

ScienceDaily — Health and medicine news

National Cancer Institute — Brain cancers

Secondary sources

Medical News Today — Medical news

News Medical — Scientific and medical news

Brain Canada — Brain research foundation

PubMed — Nitrosylcobalamin selectively targets tumors via the cobalamin transport axis

Nouvelles du Monde — Promising vitamin B12 therapy against glioblastoma, 82% without progression, June 28, 2026